Last reviewed · How we verify
ZG006
ZG006 is a monoclonal antibody targeting PD-1.
ZG006 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ZG006 |
|---|---|
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, ZG006 prevents its interaction with its ligands, PD-L1 and PD-L2, thereby releasing the inhibition of T-cell activation and proliferation, leading to enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (PHASE1)
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (PHASE1, PHASE2)
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (PHASE1, PHASE2)
- Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (PHASE3)
- Study of ZGGS34 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (PHASE1, PHASE2)
- A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer (PHASE1)
- Study of ZG006 in Participants With Neuroendocrine Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZG006 CI brief — competitive landscape report
- ZG006 updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI